Dr. Havrilesky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1000 Duke Medical Ctr
Durham, NC 27710Phone+1 919-684-8111
Education & Training
- Duke University HospitalFellowship, Gynecologic Oncology, 1999 - 2002
- Duke University HospitalResidency, Obstetrics and Gynecology, 1995 - 1999
- Duke University School of MedicineClass of 1995
Certifications & Licensure
- NC State Medical License 1998 - 2025
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
- Join now to see all
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Development & Validation of Utilities for Health States Relevant to Cervical Cancer Patients Start of enrollment: 2008 Sep 01
- Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 195 citationsOral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic ReviewJennifer M Gierisch, Remy R Coeytaux, Rachel Peragallo Urrutia, Laura J. Havrilesky, Patricia G. Moorman
Cancer Epidemiology, Biomarkers & Prevention. 2013-09-06 - 273 citationsRandomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Fact...Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui
Journal of Clinical Oncology. 2018-03-27 - 128 citationsRandomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas ...Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui
Clinical Cancer Research. 2020-08-01
Journal Articles
- Association of Medicaid Expansion with Mortality from Gynecologic CancersBenjamin B Albright, Laura J Havrilesky, Emeline M Aviki, American Journal of Obstetrics and Gynecology
Press Mentions
- Which Malnutrition Criteria to Use in Gynecologic Cancers?June 3rd, 2022
- Birth Control Pills Tied to Lower Ovarian Cancer RiskJune 7th, 2013
- The Pill Tied to Lower Ovarian Cancer RiskJune 6th, 2013
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: